Zentalis Pharmaceuticals presents positive updated clinical data for ovarian cancer treatment.

From GlobeNewswire: 2025-03-15 11:25:00

Zentalis Pharmaceuticals announced updated clinical data from Part 1b of the DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC). The data showed an ORR of ~35% and a median duration of response (mDOR) of 6.3 months. The company plans to initiate Part 2 of the trial in the first half of 2025, with registration-intent topline data expected by the end of 2026. In addition, preclinical data demonstrated synergistic effects when combining azenosertib with microtubule inhibitor-based ADCs. The presentation at the SGO Annual Meeting highlighted the potential of azenosertib as a treatment option for PROC patients overexpressing Cyclin E1.



Read more at GlobeNewswire: Zentalis Pharmaceuticals Presents Updated Clinical Data at